Forbion Growth Opportunities Fund III Cooperatief U.A., a 10% owner of Braveheart Bio, Inc. ($BRVE), reported two open-market stock purchases on August 7, 2026, that together totaled $64.8 million. The trades added 3.6 million shares to the fund's position, all at a uniform $18.00 per share. The same day, a single Form 4 filing disclosed both purchases to the Securities and Exchange Commission.
The filing detailed two separate transactions. One involved 1,680,000 shares at $18.00 each, for a total of $30,240,000. After that purchase, the fund reported holding 10,185,478 shares of $BRVE. The second transaction covered 1,920,000 shares, also priced at $18.00, amounting to $34,560,000 and resulting in a reported position of 11,640,546 shares. Together, the two outlays hit $64.8 million in a single session. Both trades were open-market buys, and the Form 4, filed on August 7, left no lag between execution and disclosure.
The same date also saw insider buying from director Christopher Viehbacher. He acquired 83,333 shares at the identical $18.00 price, for a total of $1,499,994. Afterward, he held 609,519 shares. Across the two filers, combined insider purchases of $BRVE stock on August 7 reached approximately $66.3 million, with all trades at $18.00.
Neither Forbion Growth Opportunities Fund III Cooperatief U.A. nor Christopher Viehbacher had reported any prior $BRVE trades in the available database. The August 7 filings represent the first recorded insider transactions for both parties. Viehbacher's purchase was submitted under accession number 0001470831-26-000801, while the two Forbion trades appeared together under accession number 0001193125-26-340528.
The share counts reported as held after each of Forbion's two purchases do not independently establish the chronological sequence. The 1.68-million-share and 1.92-million-share transactions might have been executed in either order. Each disclosed figure simply reflects the position size following that particular trade.
Braveheart Bio, Inc. trades under the ticker $BRVE. Company records in the database contain limited metadata, with no sector or industry classification assigned and no prior insider trading history preceding the August 7 activity. A review of STOCK Act disclosures found no congressional trades involving $BRVE.